Blood platelet RNA test could revolutionize ovarian cancer detection

NCT ID NCT06665945

Recruiting now Diagnosis Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

The SENTRY study is testing whether changes in platelet RNA (a type of genetic material in blood cells) can help diagnose ovarian cancer early. Researchers will collect blood samples from 245 women—those with ovarian masses and healthy volunteers—to see if their new test can accurately tell who has cancer. If it works, this could lead to a simple, non-invasive screening tool for a disease that is often caught too late.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Platelet RNA expression test (diagnostic test)
What this could lead to: If successful, this could lead to a simple blood test that helps detect ovarian cancer earlier, when treatment is more likely to work.
What could go wrong: This is a small, early-stage study. The test may not be accurate enough in real-world settings, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.